

Witness the Unlimited Potential of Taiwan-Japan Biotech Collaboration

In the current global wave of biotech industry development, Taiwan and Japan are both active participants with strong incentives and robust infrastructure. As the world's third largest market for biomedicine, a mature value chain has been established in Japan with both strong pharmaceutical companies and advanced basic research providers. In Taiwan, with strong entrepreneurship, an active capital market, internationalized talent, and a centralized and highly regarded healthcare system, biotechnology is building up to become one of Taiwan's most significant industries. Utilizing the complementary advantages and unlimited collaboration potential between the booming biotech industries of Taiwan and Japan, DCI Partners, a subsidiary of Daiwa Corporate Investment (DCI Group), established the "Daiwa TW-JP Biotech Fund" in 2015. Through this fund, DCI Partners is now dedicated to investing in private companies with advanced projects or platforms. Through these investments, DCI Partners aims to actively add value to the investee and facilitate increased collaboration between Taiwan and Japan.

To energize such collaboration, DCI Group is honored to organize the "Witness the Unlimited Potential of Taiwan-Japan Biotech Collaboration" forum during BioTaiwan 2017, the biggest event of the Taiwan biotech industry calendar. This forum will focus on the following topics:

- Experience from investment and value-adding activities from DCI Group, and its observation of the industry.
- Considerations, business models, and key factors to achieving a successful deal while increasing enterprise value, shared by companies or organizations with stories of successful Taiwan-Japan collaboration.
- Strategic considerations for project or business development in Japan.

With different perspectives presented and discussed at this forum, DCI Partners looks forward to realizing the huge potential and benefits from Taiwan-Japan biotech collaborations. Your participation in this event will be greatly appreciated.

Website of BioTaiwan 2017 : <https://bio-taiwan.com/en>

Website of the Event : <https://bio-taiwan.com/en/program/detail/29>

Time : 2017/06/30 (Friday) 9:00-12:00

Venue : Rm 504a, Taipei Nangang Exhibition Center

Organizer : DCI Partners (Daiwa Corporate Investment), Taiwan Bio Industry Organization

Co-organizer : Development Center for Biotechnology (DCB)

Contact person: [DCI] Brian Po-Hui Chen (+886-2-25081101), [DCB] Phoenix Wang (+886-23957977)

Please fill in the form (<https://goo.gl/iyWIDc>) for more registration information of the event

Agenda :

Time	Topic	Speaker	Remark
08:50-09:00	Registration		
09:00-09:10	Welcome Remark	<u>DCI Partners</u> Hiroki Narita, CEO	
09:10-09:30	Opening Remark	<u>Taiwan Bio Industry Organization</u> Dr. Johnsee Lee, chairman <u>Office of Science & Technology</u> <u>Executive Yuan</u> Stone Shih-Torng Ding, Deputy Executive Secretary <u>Government Officer</u> (inviting)	
09:30-09:50	Creation and management of biotech investment opportunities between Taiwan and Japan	<u>DCI Partners</u> Shuntaro Kodama, Managing Director	Established since 2015, the “Daiwa TW-JP Biotech Fund” has invested in many companies in Taiwan and Japan. In addition, coordinated by the fund management team, numerous business interaction and matching activities were facilitated, among which collaboration deals were successfully achieved and investment opportunities created. The fund and the team are now the important linkage between Taiwan and Japan biotech and investment field.
09:50-10:10	Opportunities of biotech industry in Taiwan and Japan – a perspective from International Society for Cellular therapy	<u>International Society for Cellular Therapy (ISCT)</u> Dr. Oscar Kuang-Sheng Lee, VP, Asia Region	As one of the revolutionary biotechnology in 21st century, cell therapy/regenerative medicine is actively developed not just in western country, but also in Asia with respective niche or strength. Steminent Biotherapeutics is a Taiwanese biotech company specialized in cell therapy development. A proprietary process technology for mesenchymal stem cell has been established. Based on the technology, several cell therapy products targeting severe disease are now under development. Steminent has out-licensed and achieved collaboration with a Japanese regenerative medicine company – Reprocell to co-develop and commercialize its product in Japan.
10:10-10:30	Strategic Partnership for Japan/Taiwan in Regenerative Medicine, Steminent out-licensing as a case study	<u>Steminent Biotherapeutics</u> Ryan Chang, President	
10:30-10:40	Break		
10:40-11:20	Integration of Resources in Taiwan and Japan to build up new business in CNS field	<u>National Institutes for Quantum and Radiological Science and Technology (QST)</u> Dr. Makoto Higuchi, Team Leader <u>APRINOIA Therapeutics</u> Dr. Ming-Kuei Jang, CEO (Moderator) <u>DCI</u> Brian Po-Hui Chen, Director	In the arena of biotech industry, CNS field with huge unmet medical demand is one of the most challenging sector. APRINOIA Therapeutics, an emerging biotech company established in Taiwan, focuses on CNS field with unique business strategy. Partnering with QST, with licensing of Tau targeting technology from QST and close research collaboration, APRINOIA is dedicated to develop PET imaging tracers and new therapeutic drugs for Alzheimer’s and other neurodegenerative diseases.
11:20-11:50	Strategy of Project/business Development in Japan	<u>Linical Taiwan</u> Vivian SF Lee, President & CEO	Linical is one of the first-tier clinical CRO in Japan. With extensive experience of conducting clinical trials in Japan, Linical is very familiar with the drug regulation and requirement in clinical development in Japan, helping clients in developing projects in Japan. In recent years, Linical has been expanding its business to become a global CRO. Not just establishing subsidiaries in US, EU, Linical is further expanding operational presence in Asia-Pacific such as S. Korea, Taiwan, and Singapore. Linical provides full service solutions in clinical trial and also provides consulting Services in drug development business.
11:50	Closing Remark/Networking		

*The Organizer reserves the right to change the terms and condition of the event